US biopharmaceutical company Amgen (NASDAQ:AMGN) announced on Monday that it has received marketing authorisation from the European Commission for IMDYLLTRA (tarlatamab) as a monotherapy to treat adults with extensive-stage small cell lung cancer (ES-SCLC) who require systemic therapy following disease progression on or after first-line treatment with platinum-based chemotherapy.
This approval was based on results from DeLLphi-304, the first global Phase 3 trial to demonstrate a significant survival benefit over chemotherapy in this setting.
In the trial, IMDYLLTRA reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard of care (SOC) chemotherapy as a treatment for patients with ES-SCLC who progressed on or after one line of platinum-based chemotherapy.
Amgen receives EU marketing authorisation for IMDYLLTRA in ES-SCLC
Haisco receives US FDA approval for anaesthetic Cipepofol
Hanmi signs licensing deal with Lilly for sonefpeglutide
FDA approves TREMFYA label expansion
GSK reports positive phase III data for bepirovirsen in chronic hepatitis B
Sanofi's venglustat receives FDA priority review for type 3 Gaucher disease
CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network
Ribo submits Phase 2 trial application for RBD1119 to European regulator
US FDA extends review timeline for AstraZeneca's camizestrant application
Orsini to chosen as contracted specialty pharmacy for Gilead's Hepcludex (bulevirtide-gmod)
Merz Therapeutics and Kvvit sign exclusive agreement for INBRIJA in Greater China
Lundbeck's Vyepti (eptinezumab) receives South Korean approval for preventive treatment of migraine
Eli Lilly reports positive Phase 1b results for VERVE-102
Dicot Pharma submits FDA application for LIB-01 phase 2b study